Amgen blood cancer drug succeeds in late-stage study

August 4, 2014 3:34 PM

11 0

Amgen blood cancer drug succeeds in late-stage study

(Reuters) - Amgen Inc said a late-stage study found that its blood cancer drug helped patients live significantly longer without the disease worsening, compared with standard treatment.

The world's largest biotechnology company's shares rose as much as 4.3 percent to $131.00 in premarket trading, after it released interim data for its injectable drug, Kyprolis.

Also read: The Dangerous Game of a President Picking Winners and Losers

Read more

To category page

Loading...